

SUPPLEMENTARY MATERIALS

Supplementary Figure 1




Figure S1 Basic chemical structure of flavonoids.

Supplementary Figure 2

	Allocation concealment	Baseline characteristics	Blinding of outcome assessors	Blinding of trial caregivers	Incomplete outcome data	Other sources	Random housing	Random outcome assessment	Selective outcome reporting	Sequence generation
Bulsara J 2022	?	+	?	?	+	?	?	?	+	?
Darabi P 2019	?	+	?	?	+	-	?	?	+	?
Hong G 2020	?	+	?	?	+	-	?	?	?	?
Hu T 2017	?	+	?	?	?	+	?	?	?	?
Jahan S 2016	?	+	?	?	+	-	?	?	+	?
Jahan S 2018	?	+	+	?	+	-	?	?	+	+
Liyanage GS 2021	?	+	+	?	+	-	?	?	+	?
Ma XH 2021	?	+	?	?	+	?	?	?	+	+
Mahmoud AA 2022	?	+	?	?	+	?	?	?	+	?
Manzar N 2020	?	?	?	?	+	-	?	?	+	?
Mihanfar A 2021	?	+	?	?	+	-	?	?	+	?
Moshfegh F 2022	?	+	?	?	+	+	?	?	+	+
Peng FX 2022	?	+	?	?	+	-	?	?	+	?
Rajan RK 2017	?	+	?	?	?	+	?	?	?	?
Shah KN 2015	?	+	?	?	+	-	?	?	+	?
Wang W 2019	?	+	?	?	+	?	?	?	+	?
Yu J 2019	?	+	?	?	+	?	?	?	+	?
Zheng SY 2021	?	+	?	?	+	?	?	?	+	+

Figure S2 Evaluation of quality for each study.

Supplementary Figure 3




Figure S3 Forest plot of flavonoids for FSH.

Supplementary Figure 4




Figure S4 Forest plot of flavonoids for estradiol.

Supplementary Figure 5






Figure S5 Forest plot of flavonoids for progesterone.

Supplementary Figure 6


(A)



(B)



(C)



(D)






Figure S6 Subgroup analyses of the count of cystic follicles with (A) type of flavonoids, (B) dose, (C) duration of administration, and (D) PCOS induction drug.

Supplementary Figure 7



(C)







Figure S7 Subgroup analyses of the count of corpus luteum with (A) type of flavonoids, (B) dose, (C) duration of administration, and (D) PCOS induction drug.

Supplementary Figure 8


(A)




(B)



(C)





(D)




Supplementary S8 Subgroup analyses of LHwith (A) type of flavonoids, (B) dose, (C) duration of administration, and (D) PCOS induction drug.

Supplementary Figure 9



(C)



(D)






Figure S9 Subgroup analyses of LH/FSH with (A) type of flavonoids, (B) dose, (C) duration of administration, and (D) PCOS induction drug.

Supplementary Figure 10


(A)



(B)



(C)



(D)




Figure S10 Subgroup analyses of FT with (A) type of flavonoids, (B) dose, (C) duration of administration, and (D) PCOS induction drug.

Supplementary Figure 11




Figure S11 Egger's bias test of (A) the count of atretic follicles, (B) the count of cystic follicles, (C) the count of corpus luteum, (D) LH, (E) LH/FSH, and (F) FT.

Supplementary Figure 12




Figure S12 Trim-and-fill evaluation of (A) the count of atretic follicles, (B) the count of cystic follicles, (C) the count of corpus luteum, (D) LH, (E) LH/FSH, and (F) FT.

Supplementary Figure 13




Figure S13 Possible mechanisms of flavonoids on PCOS animal models.